Citations

Clear

5626 citation(s) found for "Anderson, KS".

SWI/SNF complexes govern ontology-specific transcription factor function in MYC-subtype atypical teratoid rhabdoid tumor
Nesvick, Cody L. , Zhang, Liang , Yan, Yuqian , Hamdan, Feda H. , Ge, Jizhi, Anderson, Jacob B. , Gaspar‐Maia, Alexandre , Johnsen, Steven A. , Anderson, Jacob B , Johnsen, Steven A , Gaspar-Maia, Alexandre , Nesvick, Cody L , Wixom, Alexander Q. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | March 23, 2025 | Volume: 27 | Issue: 9 | Pages: 2445-2460

10.1093/neuonc/noaf081 | PMID 40121526 Get It

Abstract Background Atypical teratoid rhabdoid tumor (ATRT) is a deadly central nervous system embryonal tumor caused by loss of SMARCB1, a core subunit of SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complexes. SMARCB1-deficient cancers are defined by loss of cell differentiation-associated enhancers, but how SWI/SNF interacts with other arbiters of cell differentiation (specifically lineage-specific transcription factors [TFs]) remains poorly understood. Methods We leveraged a multi-omics approach, patient-derived ATRT cells, and patient-derived orthotopic xenografts to investigate the interplay of SWI/SNF with lineage-specific TFs in a clinically relevant setting. Results We observe that an activating protein 1 (AP-1)-dependent transcriptional regulatory network is lost in ATRT, and AP-1 and lineage-specific TFs TEAD1 and ZIC2 require SMARCB1 for enhancer binding. SMARCB1-dependent SWI/SNF integrates transcriptional functions of lineage-specific TFs into a core regulatory circuit that depends on the AP-1 subunit c-JUN, whose expression is determined by a SMARCB1-dependent super-enhancer that is lost in ATRT-MYC. In the absence of SMARCB1, lineage-specific TFs are sequestered to promoters, where they maintain core transcriptional programs necessary for cell survival. Targeting residual, promoter-proximal TF activity by a protein degrader of the SWI/SNF ATPase SMARCA4 or small-molecule inhibitors that indirectly inhibit AP-1 and TEAD activity abrogates expression of these networks, reducing cell viability in vitro and prolonging survival in an orthotopic patient-derived xenograft model. Conclusions These results demonstrate SWI/SNF complexes are critical for lineage-specific TF binding and activity at both promoters and enhancers. In the context of ATRT, these findings reveal a previously underappreciated therapeutic vulnerability in targeting residual promoter-proximal TF function in ATRT.
Going Back Home: Understanding the Challenges and Discrimination of Early and Mid-Career International and Puerto Rican Medical Graduates in Oncology Fields in the United States
Olazagasti, Coral , Celi, Claudia Villa , Mahtani, Arun , Velázquez, Ana I. , Sridhar, Arthi , Horiguchi, Miki , González, Mariana , Bernabe, Carolina , Abioye, Oyepeju , Dizman, Nazlı , Kiel, Lauren , Horiguchi, Miki , Gonzalez, Mariana , Bernabe, Carolina , Abioye, Oyepeju , Dizman, Nazli , Duma, Narjust , Velazquez, Ana I , Villa Celi, Claudia S , Kiel, Lauren , Florez, Narjust

Mayo Clinic

JCO Global Oncology | March 20, 2025 | Volume: No volume available | Issue: 11 | Pages: No page available

10.1200/go-24-00513 | PMID 40112258 Get It

PURPOSE Although international medical graduates (IMGs) and Puerto Rican Medical Graduates (PRMGs) comprise an integral part of the health care workforce, these individuals, particularly women, frequently face numerous types of discrimination throughout medical training and independent practice. To our knowledge, we conducted the first cross-sectional study to understand the journeys and consequences of migration faced by IMGs and PRMGs in the US oncology workforce. METHODS We developed a cross-sectional, online survey consisting of 51 multiple choice and open-ended questions that captured demographic information, professional status, period of migration to the United States, location within the United States that participants migrated to, reasons for migration, cultural adaptation, experiences of discrimination during training, and overall professional experiences in the United States. RESULTS The majority of participants cited better education, professional gains, and a lack of opportunities in participants' home country as primary reasons for migration to the United States. However, most participants, particularly women, experienced staunch assimilation to fit the mold of professional American standards; women were also particularly likely to report experiences of racial/ethnic, language, and gender discrimination during oncology training in the United States, which only marginally improved during independent practice. Despite such discrimination, most participants reported excellent professional satisfaction during training and independent practice, although only moderate personal satisfaction. Most participants decided to stay in the United States, citing reasons pertaining to enhanced professional opportunities, whereas those that returned home valued reasons relating to family and quality of life. CONCLUSION Our sobering findings underscore the need for institutional enforcement of an inclusive environment encompassing cultural humility, enactment of programs addressing barriers to socialization, immigration laws, and financial support, creation of IMG-specific support networks, and the sponsorship and promoting of minority women physicians.
Autoimmune Disorders of the Liver and Biliary Tract
Anderson, C. M. , Welle, Christopher L. , Ludwig, Daniel R. , Anderson, Mark , Khot, Rachita , Itani, Malak , Zulfiqar, Maria , Torbenson, Michael , Venkatesh, Sudhakar K. , Anderson, Cody M , Anderson, Mark A , Torbenson, Michael S , Venkatesh, Sudhakar K , Zulfiqar, Maria , Itani, Malak

Mayo Clinic

RadioGraphics | March 20, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1148/rg.240126 | PMID 40111901 Get It

Understanding the imaging appearance of autoimmune disorders of the liver and biliary tract is important to guide further workup, suggest a particular diagnosis, monitor for disease progression or response to treatment, and evaluate for complications.
Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study
Demmer, Ryan T. , Wu, Christina , Sun, Yifei , Cushman, Mary , Boyle, Rebekah, Styer, Linda M. , Bell, Taison D., Anderson, Michaela R. , Schreiner, Pamela J. , Bowler, Russell, Rock, Jean M., Bievenue, Rachel, Kandula, Namratha R. , Raffield, Laura M. , Elkind, Mitchell S.V. , Ortega, Victor E. , Woodruff, Prescott G. , Oelsner, Elizabeth C. , Wu, Chaoqi , Anderson, Michaela R , Lee, Joyce S , Xanthakis, Vanessa , Pirzada, Amber , Mantis, Nicholas J , Raffield, Laura M , Oelsner, Elizabeth C , Demmer, Ryan T , Kim, John S. , Balte, Pallavi , Tracy, Russell P. , Allen, Norrina B. , Schwartz, David A. , Lee, Joyce , Xanthakis, Vanessa , Doyle, Margaret F. , Regan, Elizabeth Anne , Make, Barry J. , Kanaya, Alka M , Wenzel, Sally E. , Coresh, Josef , Isasi, Carmen R. , Howard, Virginia J. , Cole, Shelley A. , Henderson, Joel

Mayo Clinic

Open Forum Infectious Diseases | March 20, 2025 | Volume: 12 | Issue: 3 | Pages: No page available

10.1093/ofid/ofaf123 | PMID 40124199 Get It

Abstract Despite the availability of effective vaccines and a recent decrease in annual deaths, COVID-19 remains a leading cause of death. Serological studies provide insights into host immunobiology of adaptive immune response to infection, which holds promise for identifying high-risk individuals for adverse COVID-19 outcomes. We investigated correlates of anti-nucleocapsid antibody responses following SARS-CoV-2 infection in a US population-based meta-cohort of adults participating in longstanding National Institutes of Health–funded cohort studies. Anti-nucleocapsid antibodies were measured from dried blood spots collected between February 2021 and February 2023. Among 1419 Collaborative Cohort of Cohorts for COVID-19 Research participants with prior SARS-CoV-2 infection, the mean age (standard deviation) was 65.8 (12.1), 61% were women, and 42.8% self-reported membership in a race/ethnicity minority group. The proportion of participants reactive to nucleocapsid peaked at 69% by 4 months after infection and waned to only 44% ≥12 months after infection. Higher anti-nucleocapsid antibody response was associated with older age, Hispanic or American Indian Alaskan Native (vs White) race/ethnicity, lower income, lower education, former smoking, and higher anti-spike antibody levels. Asian race (vs White) and vaccination (even after infection) were associated with lower nucleocapsid reactivity. Neither vaccine manufacturer nor common cardiometabolic comorbidities were not associated with anti-nucleocapsid response. These findings inform the underlying immunobiology of adaptive immune response to infection, as well as the potential utility of anti-nucleocapsid antibody response for clinical practice and COVID-19 serosurveillance.
Utilizing Patient Input in Rectal Cancer Trial Design
Alvarez, Janet , Zambare, Wini , George, Manju, Garcia, Reese , Gallagher, Phuong , Kitchens, Caleah , Bercz, Aron , Kim, Min Jung , Romesser, Paul B. , Cercek, Andrea , Sanoff, Hanna K. , Hong, Theodore S. , Baghdadi, Tareq Al, Shergill, Ardaman , Meyerhardt, Jeffrey A. , Horvat, Natally , Hall, William A., Smith, J. Joshua , Sanoff, Hanna , George, Thomas J , Hong, Theodore S , Yothers, Greg , Philip, Philip , Alese, Olatunji B , Shergill, Ardaman , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Horvat, Natally , Dasari, Arvind N , Shi, Qian , Schrag, Deborah , Smith, J Joshua , Romesser, Paul B , Baghdadi, Tareq Al , Kitchens, Caleah , García‐Aguilar, Julio , George, Thomas J. , Yothers, Greg , Philip, Philip A. , Alese, Olatunji B. , O’Reilly, Eileen M. , Dasari, Arvind , Shi, Qian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 20, 2025 | Volume: 117 | Issue: 7 | Pages: 1421-1428

10.1093/jnci/djaf074 | PMID 40108482 Get It

Abstract Background The treatment of locally advanced rectal cancer now includes “watch-and-wait” (WW) management for patients who exhibit a clinical complete response (cCR) to total neoadjuvant therapy (TNT). We assessed patients’ knowledge and preferences regarding WW with the goal of incorporating patient input into clinical trial design. Methods Rectal cancer patients in advocacy groups (COLONTOWN/Rectalburgh and Fight CRC) were surveyed regarding perceptions about treatment strategies, tolerable risks of treatment failure, and preferences on clinical trial design. Surveys were initially distributed in 2019, with the shift toward WW prompting re-survey of select questions in 2023. Results All respondents preferred enrollment in trials that incorporated patient input. Most respondents (76%) preferred treatment that incorporated chemotherapy escalation over radiation escalation. Furthermore, when presented with a hypothetical patient who developed a cCR after chemoradiation (without the option for WW), 58% of patients chose surgical treatment (with 100% risk of permanent ostomy and 80% chance of cure) over omission of surgery (with <80% chance of cure). In contrast, when the hypothetical patient developed a cCR after TNT (with an option for WW), 82% of patients opted for selective WW over surgery. Conclusions This work successfully integrated patient advocacy groups as a resource for obtaining patient input. Surveys revealed patients had a strong preference for chemotherapy escalation, for selective WW when offered, and for incorporation of input into future clinical trial design. These findings describe how well-informed patients approach complex medical decision-making and serve as a starting point for future studies seeking to incorporate patient voices.
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
Hernández‐Boluda, Juan Carlos , Raj, Kavita , Kenyon, Michelle , Robin, Marie , Sockel, Katja , Sánchez‐Ortega, Isabel , Arcaini, Luca , Battipaglia, Giorgia , Ciceri, Fabio , Drozd‐Sokołowska, Joanna , Funke, Vaneuza Araújo Moreira , Gangat, Naseema , Harrison, Claire , Khoury, Joseph D. , Padron, Eric , Patnaik, Mrinal M. , Pemmaraju, Naveen , Radia, Deepti , Reiter, Andreas , Tefferi, Ayalew , Vannucchi, Alessandro M., Polverelli, Nicola , Hernández-Boluda, Juan Carlos , Gurnari, Carmelo , Raj, Kavita , Czerw, Tomasz , Kenyon, Michelle , Robin, Marie , Sánchez-Ortega, Isabel , Arber, Daniel A , Battipaglia, Giorgia , Chalandon, Yves , Cross, Nicholas C P , Drozd-Sokolowska, Joanna , Funke, Vaneuza , Gangat, Naseema , Hobbs, Gabriela S , Jain, Tania , Khoury, Joseph , Kiladjian, Jean-Jacques , Kröger, Nicolaus , Malcovati, Luca , Martino, Massimo , Mesa, Ruben , Palandri, Francesca , Patnaik, Mrinal , Pemmaraju, Naveen , Scheid, Christof , Wiseman, Daniel H , Yakoub-Agha, Ibrahim , Arcaini, Luca , Polverelli, Nicola , Onida, Francesco , Gurnari, Carmelo , Ruggeri, Annalisa , Arber, Daniel A. , Duarte, Fernando Barroso , Battipaglia, Giorgia , Chalandon, Yves , Cross, Nicholas C.P. , Gagelmann, Nico , Gotlib, Jason , Guglielmelli, Paola , Hobbs, Gabriela , Jain, Tania , Kiladjian, Jean‐Jacques , Kröger, Nicolaus , Malcovati, Luca , Martino, Massimo , Mesa, Ruben A. , Orazi, Attilio , Palandri, Francesca , Passamonti, Francesco , Russo, Domenico , Scheid, Christof , Wiseman, Daniel H. , Yakoub‐Agha, Ibrahim , McLornan, Donal P.

Mayo Clinic

Blood | March 19, 2025 | Volume: 145 | Issue: 22 | Pages: 2561-2573

10.1182/blood.2024028000 | PMID 40106773 Get It

Abstract “Nonclassical” myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation. To address this gap, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised fourth edition of the (2016) World Health Organization classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia, chronic eosinophilic leukemia (CEL)/CEL, not otherwise specified (CEL-NOS), myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions with FGFR1, JAK2, ABL1, and FLT3 rearrangements, MDS/MPN with neutrophilia/atypical chronic myeloid leukemia, and MDS/MPN, NOS. For patients with MPN, NOS/MPN unclassifiable, standard recommendations for myelofibrosis should be applied. Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended on the basis of established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.
Absence of the intracellular lipolytic inhibitor G0S2 enhances intravascular triglyceride clearance and abolishes diet-induced hypertriglyceridemia
Chen, Yongbin , Johnson, Scott , Burr, Stephanie D. , Povero, Davide , Anderson, Aaron , McMahon, Cailin E., Liu, Jun , Johnson, S. M. , Liu, Jun , Johnson, Scott M., Liu, Jun

Mayo Clinic

Journal of Clinical Investigation | March 18, 2025 | Volume: 135 | Issue: 10 | Pages: No page available

10.1172/jci181754 | PMID 40100923 Get It

The interplay between intracellular and intravascular lipolysis is crucial for maintaining circulating lipid levels and systemic energy homeostasis. Adipose triglyceride lipase (ATGL) and lipoprotein lipase (LPL), the primary triglyceride (TG) lipases responsible for these two spatially separate processes, are highly expressed in adipose tissue. Yet the mechanisms underlying their coordinated regulation remain undetermined. Here, we demonstrate that genetic ablation of G0S2, a specific inhibitory protein of ATGL, completely abolished diet-induced hypertriglyceridemia and significantly attenuated atherogenesis in mice. These effects were attributable to enhanced whole-body TG clearance, not altered hepatic TG secretion. Specifically, G0S2 deletion increased circulating LPL concentration and activity, predominantly through LPL production from white adipose tissue (WAT). Strikingly, transplantation of G0S2-deficient WAT normalized plasma TG levels in mice with hypertriglyceridemia. In conjunction with improved insulin sensitivity and decreased ANGPTL4 expression, the absence of G0S2 enhanced the stability of LPL protein in adipocytes, a phenomenon that could be reversed upon ATGL inhibition. Collectively, these findings highlight the pivotal role of adipocyte G0S2 in regulating both intracellular and intravascular lipolysis, and the possibility of targeting G0S2 as a viable pharmacological approach to reducing levels of circulating TGs.
Novel Diagnosis of Isolated Cardiac Erdheim–Chester Disease by Interatrial Biopsy Using Frozen Section Examination
Singh, Jasraj , Neidert, Newton B. , Anderson, Jason H. , Layman, Andrew J. , Rech, Karen L. , Go, Ronald S. , Breen, William G. , Young, Phillip M. , Young, Jason R. , Koster, Matthew J. , Go, Ronald S , Koster, Matthew J , Young, Jason R , Rech, Karen , Anderson, Jason , Layman, Andrew J.

Mayo Clinic

Interventional Cardiology: Reviews, Research, Resources | March 17, 2025 | Volume: 20 | Issue: No issue available | Pages: No page available

10.15420/icr.2024.32 | PMID 40171021 Get It

Erdheim–Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterised by multiorgan pathological histiocytic infiltration. Cardiac involvement occurs in 40–75% of patients and increases mortality. A 55-year-old woman with chest pain and dyspnoea was found to have an interatrial septal mass and aortitis suspicious for ECD without other organ involvement. After two inadequate transcatheter interatrial biopsies were obtained using ultrasound guidance alone, diagnostic samples were successfully obtained using intraprocedural frozen section examination. The patient started genotype-targeted treatment with good response. Biopsy confirmation of ECD is required to guide treatment; however, cardiac biopsies are uncommonly performed when other organs are affected. Our unique case of isolated cardiovascular involvement highlights how frozen sectioning with multimodal intraprocedural imaging guidance can improve diagnostic yield of endomyocardial biopsies. It also highlights how diagnosis of rare conditions requires careful multidisciplinary evaluation of affected organs, procedural risk and diagnostic yield. The use of frozen sectioning can improve diagnostic yield of endomyocardial biopsies.
Representation of neuro-oncology in American neurology departments: An analysis of Grand Rounds and perspectives from faculty and residents
Neil, Elizabeth , Bruhnding, Aubree , Ahmed, Zubair , Kumthekar, Priya , Blondin, Nicholas, Patel, Chirag B, Hsu, Sigmund, Wang, Feng , Rosen, Noah , Burish, Mark J. , Corbin, Zachary , Patel, Chirag B. , Neil, Elizabeth C , Kumthekar, Priya , Grommes, Christian , Patel, Chirag B, Miao, Hongyu , Singh, Rashmi B. Halker

Mayo Clinic

Neuro-Oncology Practice | March 17, 2025 | Volume: 12 | Issue: 6 | Pages: 1121-1129

10.1093/nop/npaf033 | PMID 41458932 Get It

Abstract Background Neuro-oncology education in American neurology departments is highly variable, with no clear guidelines on appropriate practices. To better understand its current state, we focus on the perspective of departmental Grand Rounds (GR), views of adult neurology residency program directors (ANRPD), neuro-oncologists, and residents. Methods First, we obtained GR series from academic years 2017–2018 and 2018–2019 via an online search and direct emails to neurology residency programs. Second, two online surveys were dispensed to ANRPD and neuro-oncologists. Third, a cohort of neurology residents completed surveys with pre/post-didactic tests. Results Neuro-oncology consisted of 7% (28/ 411) GR in 2017–2018 and 6% (29/463) in 2018–2019; approximately 20% of institutions had no neuro-oncology GR. Twenty neuro-oncologists and 25 of the 175 ANRPDs completed the surveys. Respondents thought 1-to-4 GR annually was adequate. Thirty-five residents completed the survey. Residents might consider neuro-oncology with more exposure (77%, 27/35) and a stronger knowledge base (57%, 20/35). After 8-hours of didactics, residents demonstrated significant (P = .019) pre-/post-test improvement. Conclusions Here, we begin to define the status of several aspects of neuro-oncology education: 1 in 5 academic institutions do not have any neuro-oncology GR lectures annually, and both ANRPDs and neuro-oncologists agree that 1-to-4 lectures annually are adequate. Residents overwhelmingly stated they would be more interested in neuro-oncology with more exposure, and a pilot study of 8 hours of didactic did show knowledge improvement. While these initial datasets require confirmation in larger studies, it suggests that small changes to the current state at some institutions could have a meaningful impact.
Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma
Chakraborty, Chandraditya , Talluri, Srikanth, Binder, Moritz , Morelli, Eugenio , Encinas, Jessica , Derebail, Sanika, Samur, Anıl Aktaş , Epstein, Charles B. , Anderson, Kenneth C., Shammas, Masood A. , Fulciniti, Mariateresa , Munshi, Nikhil , Epstein, Charles , Shammas, Masood , Binder, Moritz , Morelli, Eugenio , Encinas Mayoral, Jessica , Anderson, Kenneth C. , Samur, Mehmet

Mayo Clinic

Blood | March 16, 2025 | Volume: 146 | Issue: 1 | Pages: 104-114

10.1182/blood.2024026588 | PMID 40090008 Get It

Abstract Multiple myeloma (MM) is a complex hematological malignancy characterized by genomic changes and transcriptomic dysregulation. Initial exome sequencing approaches have failed to identify any single, frequent (>25%) mutation in the coding genome. However, using whole-genome sequencing, we found that one of the genomic regions most frequently mutated (62% of the patients with MM) was the 5′ untranslated region and/or intron 1 of the BCL7A gene. RNA-sequencing data from a large cohort suggest a loss of BCL7A expression in a large majority of patients with MM as compared with normal plasma cells. BCL7A loss of function in a panel of MM cell lines led to a highly proliferative phenotype in vitro and in vivo, whereas its ectopic expression significantly reduced cell viability, suggesting a tumor suppressor function for BCL7A in MM. We studied the cellular and molecular effects of BCL7A loss and observed that it endows myeloma cells with proliferative potential in cooperation with the plasma cell–defining transcription factor IRF4. BCL7A is involved in a direct protein-protein interaction with IRF4, limiting its DNA-binding activity. Loss of BCL7A thus enhances the expression of IRF4-associated cytokines and reduces mitochondrial metabolism and reactive oxygen species levels. Our study therefore suggests that BCL7A loss provides the necessary molecular change to allow IRF4-mediated transcriptional activity and MM cell growth and survival.